Pfizer to market Biohaven’s migraine drugs outside US
Under the terms of the agreement, Biohaven will continue to solely market the migraine drug rimegepant in the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Nov 21
Under the terms of the agreement, Biohaven will continue to solely market the migraine drug rimegepant in the…
10 Nov 21
The procurement is subject to US Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) or approval of…
09 Nov 21
The financing from Blackstone will support Autolus’ clinical development of obe-cel for relapsed / refractory adult ALL and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 21
In the Phase 2/3 trial, Paxlovid reduced 89% risk of Covid-19-related hospitalisation or death compared to placebo, within…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 21
The new manufacturing facility will feature advanced technologies and sustainability advancements, to produce medicines for the US
05 Nov 21
The approval was based on positive results from the Phase 3 MOVe-OUT trial and follows the MHRA and…
05 Nov 21
Novartis will sell 53.3 million bearer shares of Roche’s common stock, bringing an end to its investment in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Nov 21
Novartis will leverage Dunad's platform to generate novel oral covalent and protein degrading small molecule drugs across multiple…
03 Nov 21
The antibody therapy combination has been granted FDA EUA, to treat mild to moderate Covid-19 or for post-exposure…
02 Nov 21
Under the agreement, Merck will gain exclusive rights to develop, manufacture and commercialise surrogate cytokine agonists for a…